Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Lipari Mining and SpurChain Partner to Tokenize Natural Diamond Production (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Erasca Inc ERAS

Healthcare Biotechnology
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and... see more

Recent & Breaking News (NDAQ:ERAS)

Erasca Announces Issuance of a U.S. Patent Covering Pan-RAS Molecular Glue ERAS-0015

GlobeNewswire 1 day ago

Erasca to Present at Upcoming Conferences in November

GlobeNewswire 3 days ago

Erasca to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

GlobeNewswire September 2, 2025

Erasca Reports Second Quarter 2025 Business Updates and Financial Results

GlobeNewswire August 12, 2025

Erasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001

GlobeNewswire June 2, 2025

Erasca to Present at Upcoming Investor Conferences in June

GlobeNewswire May 29, 2025

Erasca Reports First Quarter 2025 Business Updates and Financial Results

GlobeNewswire May 13, 2025

Erasca Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash Runway

GlobeNewswire May 13, 2025

Erasca to Present at the Bank of America Securities Health Care Conference

GlobeNewswire May 7, 2025

Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting

GlobeNewswire April 29, 2025

Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting

GlobeNewswire March 25, 2025

Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results

GlobeNewswire March 20, 2025

Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference

GlobeNewswire January 31, 2025

Erasca to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 7, 2025

Erasca Reports Third Quarter 2024 Business Updates and Financial Results

GlobeNewswire November 12, 2024

Erasca to Present at Upcoming Investor Conferences

GlobeNewswire November 5, 2024

Erasca Announces Strong Momentum for Naporafenib and RAS Targeting Franchise

GlobeNewswire October 24, 2024

Erasca to Present Preliminary SEACRAFT-1 Phase 1 Data for Naporafenib Plus Trametinib in RAS Q61X Mutant Solid Tumors as Oral Presentation at 36th EORTC-NCI-AACR Symposium

GlobeNewswire September 25, 2024

Erasca to Present at Upcoming Investor Conferences in September

GlobeNewswire August 29, 2024

Erasca Reports Second Quarter 2024 Business Updates and Financial Results

GlobeNewswire August 12, 2024